Why the study?
Does rivaroxaban improve safety and effectiveness compared to standard of care for the prophylaxis of venous thromboembolism in patients after major orthopedic surgery of hip or knee?
Does rivaroxaban improve safety and effectiveness compared to standard of care for the prophylaxis of venous thromboembolism in patients after major orthopedic surgery of hip or knee?
The XAMOS study is designed to provide real-world evidence on the safety and effectiveness of rivaroxaban for VTE prophylaxis after major orthopedic surgery, supplementing the Phase III RECORD trials.
Answers are grounded in this paper and cite their sources.
XAMOS supplies real-world rivaroxaban data post-orthopedic surgery; leaves open confirmation of RECORD benefits in unselected patients.
Venous thromboembolism is a frequent and potentially life-threatening complication of orthopedic surgery. Rivaroxaban is an oral direct factor Xa inhibitor, which was shown to be effective for the prevention of venous thromboembolism after elective hip and knee arthroplasty in the RECORD study program. Rivaroxaban has the potential to overcome the limitations of the current standards of care in the prevention of venous thromboembolism. XAMOS (Xarelto(®) in the prophylaxis of post-surgical venous thromboembolism after elective major orthopedic surgery of hip or knee) is an international, noninterventional, parallel-group study to gain insight into the safety (major bleeding, side effects) and effectiveness (prevention of symptomatic thromboembolic events) of rivaroxaban in daily clinical practice. XAMOS will follow 15,000 patients after major orthopedic surgery in approximately 200 centers worldwide, with about 7500 patients receiving rivaroxaban and about 7500 standard of care. XAMOS will supplement the clinical data obtained in the Phase III RECORD 1, 2, 3, and 4 trials in which rivaroxaban was shown to be superior for the primary efficacy endpoints, and with a safety profile similar to that of enoxaparin after hip or knee replacement surgery. XAMOS was started in 2009 and will complete recruitment and follow-up in 2011.
No takes yet. Share an insight, caveat, or question.
Bramlage et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: